Chelsea Ma, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ma’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A145259 · Current
Licensed to practise in California · since 2016 · expires 2028-03-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$166,244
Medicare paid this office $166,244 for 836 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 333 | $40,658 | $86 |
| Short return visit (20+ min) | 407 | $32,597 | $59 |
| Destruction of precancer skin growth, 1 growth | 312 | $18,015 | $44 |
| New patient visit (45+ min) | 135 | $15,213 | $113 |
| Destruction of skin growth, 1-14 growths | 181 | $13,812 | $67 |
See all 16 services
| Return visit (30+ min) | 333 | $40,658 | $86 |
| Short return visit (20+ min) | 407 | $32,597 | $59 |
| Destruction of precancer skin growth, 1 growth | 312 | $18,015 | $44 |
| New patient visit (45+ min) | 135 | $15,213 | $113 |
| Destruction of skin growth, 1-14 growths | 181 | $13,812 | $67 |
| New patient visit (30+ min) | 133 | $8,468 | $64 |
| Destruction of precancer skin growth, 2-14 growths | 285 | $8,460 | $3 |
| Destruction of precancer skin growth, 15 or more growths | 61 | $7,119 | $92 |
| Biopsy of related skin growth, first growth | 130 | $4,478 | $30 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 22 | $3,511 | $160 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 15 | $1,688 | $94 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 28 | $1,541 | $55 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 17 | $1,282 | $75 |
| Injection into skin growth, 1-7 growths | 28 | $831 | $23 |
| Punch biopsy, first skin growth | 15 | $818 | $48 |
| Biopsy of related skin growth, each additional growth | 22 | $814 | $26 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 412 | More than 85% of doctors who do this |
| Removal or shaving of skin growth | 33 | More than 76% of doctors who do this |
| Skin biopsy | 107 | More than 77% of doctors who do this |
Who their Medicare patients are
836 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 12% · Women 59% · Also on Medicaid 12% · Health risk score 1.08. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 61% · Diabetes 24% · Chronic kidney disease 22% · Coronary heart disease 18% · Depression 15% · Cancer 14% · Atrial fibrillation 12% · Heart failure 9% · COPD 8% · Stroke 5% · Dementia 3%.
The office billed $786,399, Medicare allowed $237,580 and paid $166,244; for 5,214 services of 51 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 836 | 5,214 | 75 | 1.08 | $786,399 | $166,244 |
| 2023 | 690 | 5,249 | 74 | 1.14 | $972,027 | $153,798 |
| 2022 | 710 | 5,193 | 74 | 1.16 | $1,163,679 | $147,574 |
| 2021 | 567 | 3,177 | 73 | 1.09 | $723,614 | $113,852 |
| 2020 | 235 | 1,167 | 73 | 1.30 | $222,557 | $31,385 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 298 | $40,449 | $89 |
| Short return visit (20+ min) | 345 | $30,303 | $63 |
| Destruction of precancer skin growth, 1 growth | 259 | $17,283 | $46 |
| Destruction of skin growth, 1-14 growths | 139 | $12,702 | $74 |
| New patient visit (45+ min) | 101 | $12,493 | $124 |
| Destruction of precancer skin growth, 2-14 growths | 250 | $9,363 | $3 |
| New patient visit (30+ min) | 130 | $8,704 | $67 |
| Biopsy of related skin growth, first growth | 139 | $5,758 | $37 |
| Destruction of precancer skin growth, 15 or more growths | 17 | $2,017 | $96 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 11 | $1,958 | $178 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $1,573 | $121 |
| Injection into skin growth, 1-7 growths | 31 | $1,210 | $26 |
| Biopsy of related skin growth, each additional growth | 25 | $1,008 | $28 |
| Telehealth originating site facility fee | 38 | $920 | $22 |
| Punch biopsy, first skin growth | 13 | $431 | $33 |
2022: 14 services
| Return visit (30+ min) | 298 | $38,383 | $89 |
| Short return visit (20+ min) | 304 | $22,904 | $57 |
| Destruction of precancer skin growth, 1 growth | 264 | $16,279 | $43 |
| New patient visit (45+ min) | 146 | $15,649 | $107 |
| Destruction of skin growth, 1-14 growths | 152 | $12,207 | $65 |
| New patient visit (30+ min) | 148 | $10,525 | $71 |
| Destruction of precancer skin growth, 2-14 growths | 244 | $9,491 | $3 |
| Biopsy of related skin growth, first growth | 172 | $8,613 | $44 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $2,255 | $173 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,602 | $94 |
| Biopsy of related skin growth, each additional growth | 40 | $1,528 | $28 |
| Injection into skin growth, 1-7 growths | 28 | $1,048 | $22 |
| Punch biopsy, first skin growth | 12 | $645 | $54 |
| Telehealth originating site facility fee | 12 | $260 | $20 |
2021: 11 services
| Return visit (30+ min) | 216 | $29,711 | $96 |
| New patient visit (45+ min) | 159 | $19,102 | $120 |
| Short return visit (20+ min) | 180 | $12,786 | $58 |
| New patient visit (30+ min) | 152 | $11,055 | $73 |
| Destruction of precancer skin growth, 1 growth | 189 | $10,764 | $43 |
| Destruction of skin growth, 1-14 growths | 106 | $8,458 | $69 |
| Biopsy of related skin growth, first growth | 126 | $5,942 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 165 | $4,993 | $3 |
| Injection into skin growth, 1-7 growths | 36 | $1,771 | $32 |
| Biopsy of related skin growth, each additional growth | 40 | $1,428 | $25 |
| Punch biopsy, first skin growth | 20 | $1,359 | $68 |
2020: 8 services
| New patient visit (30+ min) | 93 | $6,886 | $74 |
| Return visit (30+ min) | 69 | $5,700 | $81 |
| Destruction of precancer skin growth, 1 growth | 91 | $4,088 | $43 |
| Destruction of skin growth, 1-14 growths | 54 | $3,807 | $71 |
| Short return visit (20+ min) | 60 | $3,068 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 87 | $2,054 | $3 |
| Biopsy of related skin growth, first growth | 47 | $1,796 | $37 |
| New patient visit (15+ min) | 17 | $713 | $42 |
Medicaid work
$6,319 in 2024
Medicaid paid $6,319 for 75 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 75 | $6,319 |
| 2024 | 75 | 1 | 16 | $6,319 |
| 2023 | 136 | 1 | 22 | $6,953 |
| 2022 | 112 | 1 | 19 | $6,619 |
| 2021 | 45 | 1 | 17 | $2,363 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 136 | $6,953 |
2022
| Return visit (30+ min) | 112 | $6,619 |
2021
| Return visit (30+ min) | 45 | $2,363 |
Drugs they prescribed that Part D paid
$1,004,300
Pharmacies billed $1,004,300 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,095 generic and fewer than 11 brand-name prescriptions · $1,004,300 in drug cost · 78 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 18 | $362,009 | $20,112 |
| Dupixent | 71 | $263,099 | $3,706 |
| Tremfya | 14 | $192,259 | $13,733 |
| Dupixent | 25 | $94,225 | $3,769 |
| Clobetasol Propionate | 109 | $5,770 | $53 |
See all 27 drugs
| Skyrizi | 18 | $362,009 | $20,112 |
| Dupixent | 71 | $263,099 | $3,706 |
| Tremfya | 14 | $192,259 | $13,733 |
| Dupixent | 25 | $94,225 | $3,769 |
| Clobetasol Propionate | 109 | $5,770 | $53 |
| Tretinoin | 50 | $5,590 | $112 |
| Tacrolimus | 27 | $3,947 | $146 |
| Fluorouracil | 46 | $3,779 | $82 |
| Fluocinonide | 78 | $3,070 | $39 |
| Ketoconazole | 178 | $2,590 | $15 |
| Doxycycline Hyclate | 69 | $1,246 | $18 |
| Azelaic Acid | 15 | $1,222 | $81 |
| Ciclopirox | 32 | $1,206 | $38 |
| Desonide | 23 | $951 | $41 |
| Triamcinolone Acetonide | 93 | $914 | $10 |
| Metronidazole | 16 | $720 | $45 |
| Clindamycin Phosphate | 21 | $576 | $27 |
| Econazole Nitrate | 13 | $433 | $33 |
| Hydrocortisone | 87 | $390 | $4 |
| Imiquimod | 14 | $360 | $26 |
| Spironolactone | 24 | $354 | $15 |
| Mupirocin | 28 | $233 | $8 |
| Valacyclovir | 15 | $224 | $15 |
| Minoxidil | 14 | $193 | $14 |
| Ciclopirox | 13 | $186 | $14 |
| Finasteride | 12 | $134 | $11 |
| Gabapentin | 11 | $103 | $9 |
Year by year
| 2024 | 1,274 | 394 | None | None | $1,004,300 |
| 2023 | 1,247 | 361 | None | 13% | $1,173,828 |
| 2022 | 1,141 | 336 | 0% (0) | 11% | $888,082 |
| 2021 | 903 | 283 | 0% (0) | 11% | $283,405 |
| 2020 | 284 | 129 | 0% (0) | 15% | $168,156 |
| 2019 | 338 | 159 | None | 17% | $290,425 |
| 2018 | 467 | 188 | 0% (0) | 20% | $424,213 |
| 2017 | 241 | 110 | None | 18% | $246,099 |
| 2016 | 89 | 27 | None | None | $4,198 |
| 2015 | 35 | 18 | None | None | $1,062 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Skyrizi | 20 | $436,816 | $21,841 |
| Dupixent | 39 | $150,172 | $3,851 |
| Dupixent | 24 | $92,389 | $3,850 |
| Otezla | 12 | $60,906 | $5,075 |
| Pimecrolimus | 24 | $11,807 | $492 |
| Clobetasol Propionate | 104 | $9,828 | $95 |
| Tacrolimus | 31 | $9,324 | $301 |
| Tretinoin | 64 | $7,533 | $118 |
| Fluocinonide | 69 | $4,065 | $59 |
| Calcipotriene | 13 | $3,308 | $254 |
| Fluorouracil | 33 | $3,272 | $99 |
| Ketoconazole | 152 | $2,925 | $19 |
| Doxycycline Hyclate | 57 | $2,097 | $37 |
| Clindamycin Phosphate | 32 | $1,272 | $40 |
| Triamcinolone Acetonide | 84 | $1,247 | $15 |
| Ciclopirox | 26 | $1,074 | $41 |
| Imiquimod | 15 | $907 | $60 |
| Azelaic Acid | 13 | $872 | $67 |
| Metronidazole | 12 | $742 | $62 |
| Econazole Nitrate | 17 | $570 | $34 |
| Spironolactone | 25 | $570 | $23 |
| Mupirocin | 47 | $536 | $11 |
| Desonide | 13 | $520 | $40 |
| Hydrocortisone | 76 | $439 | $6 |
| Ciclopirox | 11 | $364 | $33 |
| Minocycline | 12 | $321 | $27 |
| Clotrimazole | 19 | $270 | $14 |
| Gabapentin | 20 | $269 | $13 |
| Finasteride | 11 | $197 | $18 |
2022: 29 drugs
| Skyrizi | 16 | $343,653 | $21,478 |
| Cosentyx Pen (2 Pens) | 15 | $124,205 | $8,280 |
| Dupixent | 18 | $65,456 | $3,636 |
| Dupixent | 17 | $60,269 | $3,545 |
| Tacrolimus | 38 | $10,320 | $272 |
| Acitretin | 11 | $10,075 | $916 |
| Fluocinonide | 98 | $7,751 | $79 |
| Fluorouracil | 45 | $4,499 | $100 |
| Tretinoin | 39 | $4,283 | $110 |
| Clobetasol Propionate | 66 | $3,904 | $59 |
| Ivermectin | 13 | $3,865 | $297 |
| Doxycycline Hyclate | 62 | $2,873 | $46 |
| Ketoconazole | 144 | $2,729 | $19 |
| Fluocinolone Acetonide | 32 | $2,438 | $76 |
| Clindamycin Phosphate | 33 | $2,030 | $62 |
| Betamethasone Diprop Augmented | 12 | $1,834 | $153 |
| Triamcinolone Acetonide | 78 | $1,308 | $17 |
| Metronidazole | 15 | $959 | $64 |
| Dutasteride | 16 | $941 | $59 |
| Betamethasone Dipropionate | 11 | $769 | $70 |
| Hydroxychloroquine Sulfate | 17 | $695 | $41 |
| Fluocinolone Acetonide | 12 | $690 | $58 |
| Ciclopirox | 14 | $599 | $43 |
| Spironolactone | 19 | $458 | $24 |
| Hydrocortisone | 74 | $418 | $6 |
| Ciclopirox | 14 | $267 | $19 |
| Minocycline | 11 | $225 | $20 |
| Mupirocin | 11 | $180 | $16 |
| Gabapentin | 18 | $120 | $7 |
2021: 19 drugs
| Otezla | 11 | $44,840 | $4,076 |
| Dupixent | 13 | $41,997 | $3,231 |
| Tacrolimus | 40 | $9,629 | $241 |
| Clobetasol Propionate | 85 | $5,312 | $62 |
| Fluorouracil | 42 | $4,209 | $100 |
| Fluocinonide | 61 | $3,147 | $52 |
| Tretinoin | 19 | $2,166 | $114 |
| Betamethasone Dipropionate | 23 | $2,031 | $88 |
| Clindamycin Phosphate | 33 | $2,000 | $61 |
| Ketoconazole | 91 | $1,874 | $21 |
| Doxycycline Hyclate | 49 | $1,644 | $34 |
| Triamcinolone Acetonide | 70 | $1,262 | $18 |
| Desoximetasone | 11 | $871 | $79 |
| Fluocinolone Acetonide | 20 | $626 | $31 |
| Clotrimazole | 26 | $473 | $18 |
| Spironolactone | 16 | $418 | $26 |
| Hydrocortisone | 59 | $348 | $6 |
| Ciclopirox | 17 | $244 | $14 |
| Mupirocin | 18 | $148 | $8 |
2020: 8 drugs
| Fluorouracil | 19 | $3,599 | $189 |
| Clobetasol Propionate | 37 | $2,128 | $58 |
| Fluocinonide | 25 | $1,656 | $66 |
| Metronidazole | 11 | $1,530 | $139 |
| Doxycycline Hyclate | 14 | $756 | $54 |
| Triamcinolone Acetonide | 29 | $700 | $24 |
| Ketoconazole | 19 | $357 | $19 |
| Hydrocortisone | 18 | $111 | $6 |
2019: 10 drugs
| Clobetasol Propionate | 23 | $5,253 | $228 |
| Halobetasol Propionate | 11 | $1,958 | $178 |
| Fluorouracil | 20 | $1,885 | $94 |
| Doxycycline Hyclate | 17 | $1,532 | $90 |
| Fluocinonide | 19 | $881 | $46 |
| Triamcinolone Acetonide | 28 | $478 | $17 |
| Doxepin | 17 | $434 | $26 |
| Ketoconazole | 20 | $352 | $18 |
| Hydroxyzine | 19 | $145 | $8 |
| Hydrocortisone | 16 | $94 | $6 |
2018: 11 drugs
| Humira | 13 | $170,425 | $13,110 |
| Cosentyx Pen (2 Pens) | 11 | $65,621 | $5,966 |
| Clobetasol Propionate | 44 | $8,724 | $198 |
| Halobetasol Propionate | 20 | $4,250 | $213 |
| Tacrolimus | 11 | $3,015 | $274 |
| Betamethasone Dipropionate | 15 | $2,023 | $135 |
| Fluocinonide | 25 | $1,673 | $67 |
| Triamcinolone Acetonide | 64 | $1,431 | $22 |
| Ketoconazole | 37 | $607 | $16 |
| Hydroxyzine | 18 | $114 | $6 |
| Hydrocortisone | 16 | $110 | $7 |
2017: 5 drugs
| Humira | 14 | $94,065 | $6,719 |
| Clobetasol Propionate | 27 | $5,298 | $196 |
| Triamcinolone Acetonide | 32 | $598 | $19 |
| Ketoconazole | 11 | $285 | $26 |
| Lisinopril | 11 | $28 | $3 |
Money from drug and device companies
$548 in 2025
| 2025 | 4 | 4 | None | $548 |
| 2024 | 3 | 6 | None | $668 |
| 2023 | 4 | 20 | $5,610 | $7,742 |
| 2020 | 1 | 1 | None | $98 |
| 2019 | 4 | 6 | None | $531 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Organon | Vtama | $168 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $150 | 1 payment
|
| Abbvie | Rinvoq | $128 | 1 payment
|
| Amgen | None | $102 | 1 payment
|
See all 4 published payments
| Abbvie | Meals · 2025-10-21 | Rinvoq | $128 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-29 | Sotyktu | $150 |
| Organon | Meals · 2025-03-25 | Vtama | $168 |
| Amgen | Meals · 2025-02-25 | None | $102 |
See earlier years (2024, 2023, 2020, 2019)
2024: $668
| Amgen | Otezla | $337 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $284 | 2 payments
|
| Genzyme | Dupixent | $47 | 1 payment
|
2023: $7,742
| E.R. Squibb & Sons L.L.C. | Sotyktu | $7,537 | 16 payments
|
| Amgen | Otezla | $142 | 1 payment
|
| Genzyme | Dupixent | $32 | 1 payment
|
| Pfizer | Cibinqo | $31 | 2 payments
|
2020: $98
| AbbVie | Skyrizi | $98 | 1 payment
|
2019: $531
| AbbVie | Skyrizi | $288 | 3 payments
|
| Galderma Laboratories L.P. | Epiduo Forte | $112 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $101 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Altreno | $30 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1871936575
- Licence
- CA A145259, MA 264303California A145259: Current · expires 2028-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Internal medicine (207R00000X)
- Mailing address
- 440 Broadway St Fl B4, Redwood City, CA, 94063
- NPI first listed
- 2013-04-11
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Deaconess Rd, Boston, MA, 02215 · 440 Broadway St Fl B4, Redwood City, CA, 94063 · 3301 C St Ste 1400, Sacramento, CA, 95816